



May 9, 2023

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

Sub: Disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').

In compliance with Regulation 23(9) of Listing Regulations, we are pleased to enclose in the prescribed format, disclosure of Related Party Transactions for the six-months ended March 31, 2023.

The above is for your information and dissemination.

Thanking You,

For LUPIN LIMITED

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl.: a/a.

Related party transactions for the period Oct 1, 2022 to Mar 31, 2023

Related party transactions for the period Oct 1, 2022 to Mar 31, 2023										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
Sr No.	Details of the party (listed entity/subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
392	Novel Laboratories, Inc., USA		Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	Not Applicable	34.78	0.00	0.00									
393	Novel Laboratories, Inc., USA		Lupin Inc., USA		Fellow Subsidiary	Any other transaction	Expenses incurred on their behalf recovered	Not Applicable	75.87	0.00	0.00									
394	Novel Laboratories, Inc., USA		Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES	Not Applicable	0.00	0.62	1.95									
395	Novel Laboratories, Inc., USA		Lupin Inc., USA		Fellow Subsidiary	Any other transaction	TRADE RECEIVABLES	Not Applicable	0.00	1414.60	1776.00									
396	Novel Laboratories, Inc., USA		Lupin Management, Inc., USA		Fellow Subsidiary	Any other transaction	TRADE PAYABLES	Not Applicable	0.00	11.82	14.68									
397	Lupin Inc., USA		Lupin Pharmaceuticals, Inc., USA		Fellow Subsidiary	Investment		Not Applicable	0.00	610.42	610.42									
398	Lupin Inc., USA		Lupin Research Inc., USA		Fellow Subsidiary	Investment		Not Applicable	0.00	769.10	769.13									
399	Lupin Inc., USA		Novel Laboratories, Inc., USA		Fellow Subsidiary	Investment		Not Applicable	0.00	6172.57	6172.57									
Total value of transaction during the reporting period									70967.87156											